Total Payments
$12,578
2024 Payments
$1,415
Companies
43
Transactions
332
Medicare Patients
3,437
Medicare Billing
$984,197
Payment Breakdown by Category
Food & Beverage$6,045 (48.1%)
Gifts$1,973 (15.7%)
Education$1,795 (14.3%)
Other$1,515 (12.0%)
Consulting$1,225 (9.7%)
Travel$25.00 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,045 | 276 | 48.1% |
| Gift | $1,973 | 15 | 15.7% |
| Education | $1,795 | 22 | 14.3% |
| Long term medical supply or device loan | $1,515 | 17 | 12.0% |
| Consulting Fee | $1,225 | 1 | 9.7% |
| Travel and Lodging | $25.00 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,778 | 46 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,643 | 8 | $0 (2022) |
| Janssen Biotech, Inc. | $820.21 | 32 | $0 (2024) |
| Incyte Corporation | $717.28 | 10 | $0 (2024) |
| GENZYME CORPORATION | $626.02 | 25 | $0 (2024) |
| PFIZER INC. | $546.73 | 27 | $0 (2024) |
| Eisai Inc. | $434.26 | 23 | $0 (2024) |
| Astellas Pharma US Inc | $412.69 | 10 | $0 (2023) |
| Amgen Inc. | $406.51 | 16 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $387.95 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,415 | 61 | PFIZER INC. ($194.59) |
| 2023 | $1,789 | 69 | Novartis Pharmaceuticals Corporation ($280.58) |
| 2022 | $2,060 | 77 | Novartis Pharmaceuticals Corporation ($384.09) |
| 2021 | $2,383 | 60 | Novartis Pharmaceuticals Corporation ($1,081) |
| 2020 | $251.77 | 9 | Novartis Pharmaceuticals Corporation ($99.70) |
| 2019 | $1,388 | 17 | Novartis Pharmaceuticals Corporation ($989.14) |
| 2018 | $2,862 | 26 | Takeda Pharmaceuticals U.S.A., Inc. ($1,523) |
| 2017 | $429.44 | 13 | Incyte Corporation ($99.95) |
All Payment Transactions
332 individual payment records from CMS Open Payments — Page 14 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/07/2017 | INSYS Therapeutics Inc | SYNDROS (Drug) | Food and Beverage | In-kind items and services | $11.90 | General |
| Category: Chemotherapy-Induced Nausea and Vomiting | ||||||
| 07/21/2017 | Incyte Corporation | — | Education | Cash or cash equivalent | $99.95 | General |
| 07/17/2017 | Novartis Pharmaceuticals Corporation | AFINITOR (Drug), SANDOSTATIN LAR | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: ONCOLOGY | ||||||
| 03/09/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: ONCOLOGY | ||||||
| 03/02/2017 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Food and Beverage | In-kind items and services | $12.13 | General |
| Category: Immunology | ||||||
| 01/26/2017 | Amgen Inc. | Nplate (Biological), Prolia, XGEVA | Food and Beverage | In-kind items and services | $30.67 | General |
| Category: Hematology | ||||||
| 01/05/2017 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 907 | 3,570 | $465,128 | $225,234 |
| 2022 | 15 | 897 | 4,077 | $506,401 | $233,777 |
| 2021 | 14 | 801 | 4,039 | $514,918 | $248,491 |
| 2020 | 14 | 832 | 4,268 | $601,466 | $276,696 |
Total Patients
3,437
Total Services
15,954
Medicare Billing
$984,197
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 166 | 523 | $117,745 | $55,473 | 47.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 124 | 761 | $118,558 | $54,496 | 46.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 113 | 552 | $70,838 | $44,010 | 62.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 119 | 143 | $42,185 | $21,886 | 51.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 82 | 118 | $23,364 | $13,057 | 55.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 24 | 197 | $16,520 | $10,152 | 61.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 14 | 100 | $20,000 | $6,184 | 30.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 40 | 42 | $10,710 | $4,907 | 45.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $8,867 | $4,521 | 51.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 41 | 340 | $18,840 | $4,401 | 23.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 113 | 503 | $7,500 | $4,225 | 56.3% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 13 | 100 | $10,000 | $1,920 | 19.2% |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | Office | 2023 | 13 | 99 | $0.99 | $0.99 | 100.0% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 13 | 60 | $0.60 | $0.60 | 100.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 143 | 562 | $126,450 | $52,872 | 41.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 117 | 809 | $126,920 | $52,358 | 41.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 117 | 588 | $76,458 | $48,880 | 63.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 109 | 135 | $39,825 | $24,417 | 61.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 46 | 269 | $21,908 | $14,299 | 65.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 22 | 184 | $32,425 | $12,342 | 38.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 56 | 75 | $15,056 | $8,555 | 56.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 49 | 429 | $23,595 | $5,768 | 24.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 40 | 42 | $10,857 | $5,189 | 47.8% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2022 | 21 | 178 | $17,800 | $3,585 | 20.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $4,750 | $2,974 | 62.6% |
About Dr. Hitendra Rambhia, MD
Dr. Hitendra Rambhia, MD is a Hematology & Oncology healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1629061155.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hitendra Rambhia, MD has received a total of $12,578 in payments from pharmaceutical and medical device companies, with $1,415 received in 2024. These payments were reported across 332 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($6,045).
As a Medicare-enrolled provider, Rambhia has provided services to 3,437 Medicare beneficiaries, totaling 15,954 services with total Medicare billing of $984,197. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Brooklyn, NY
- Active Since 08/30/2005
- Last Updated 10/22/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1629061155
Products in Payments
- KISQALI (Drug) $3,407
- NINLARO (Drug) $1,433
- Lenvima (Drug) $434.26
- JEVTANA (Drug) $427.02
- DARZALEX (Biological) $328.38
- ERLEADA (Drug) $306.58
- OPDIVO (Biological) $262.72
- SARCLISA (Biological) $203.95
- Nplate (Biological) $203.38
- BOSULIF (Drug) $181.35
- LUMAKRAS (Drug) $159.57
- KEYTRUDA (Biological) $147.51
- Doptelet (Drug) $143.66
- XTANDI (Drug) $130.33
- KRAZATI (Drug) $128.72
- TAGRISSO (Drug) $125.77
- XALKORI (Drug) $114.60
- IBRANCE (Drug) $113.49
- VELCADE (Drug) $111.24
- IMBRUVICA (Drug) $105.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Brooklyn
Perry Cook, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Yiwu Huang, Md, MD
Hematology & Oncology — Payments: $268,275
Hematology & Oncology $268,275
Dr. Ilya Blokh, M.d, M.D
Hematology & Oncology — Payments: $191,276
Hematology & Oncology $191,276
Songchuan Guo, M.d, M.D
Hematology & Oncology — Payments: $106,907
Hematology & Oncology $106,907
Yiqing Xu, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $51,145
Hematology & Oncology $51,145
Dr. Azriel Hirschfeld, M.d, M.D
Hematology & Oncology — Payments: $48,699
Hematology & Oncology $48,699